Using a Novel CDST to Guide the Assessment and Management of Low-/High-Risk Ulcerative Colitis

Program Overview

Clinical care pathways, based on extensive research, provide clear guidance on escalation of therapy for patients with mild ulcerative colitis (UC); however, in patients with moderate-to-severe UC, the selection of treatment is less clear. Recently a clinical decision support tool (CDST) has been developed using key clinical imaging and laboratory markers. This tool is specifically designed for patients with high burden of disease – namely those at high risk of colectomy. The tool assesses disease burden, uses risk and clinical/laboratory data to predict outcomes for certain drugs, and includes additional resources explaining how the prediction is calculated. Join Dr. Dubinsky in a virtual demonstration of the tool using patient case vignettes.

Credit Expired

CE Credit Expired

Expires: February 13, 2021

Target Audience

This activity is intended for clinicians who manage patients with inflammatory bowel disease (IBD).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply novel, predictive decision support tools to stratify patients with inflammatory bowel disease (IBD) based on complication risk and disease severity in order to inform appropriate treatment initiation and timing
Integrate biologics into the treatment regimen for IBD based on individual probability of response to specific biologics

Activity Faculty

Parambir Dulai, MD (Chair)

Assistant Professor
UC San Diego School of Medicine
San Diego, CA

Joshua Rubin, MD (Co-Chair)

Assistant Clinical Professor
UC San Diego School of Medicine
San Diego, CA

Marla C. Dubinsky, MD

Professor, Pediatrics and Medicine
Chief, Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine
Mount Sinai Hospital
New York, NY

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Privacy | Terms of Use